These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23385859

  • 1. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M, Wynes MW, Hirsch FR.
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [Abstract] [Full Text] [Related]

  • 2. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 3. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L.
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [Abstract] [Full Text] [Related]

  • 4. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 7. Treatment and detection of ALK-rearranged NSCLC.
    Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [Abstract] [Full Text] [Related]

  • 8. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 9. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [Abstract] [Full Text] [Related]

  • 10. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI, Gautschi O.
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [Abstract] [Full Text] [Related]

  • 13. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM, Rudin CM.
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [Abstract] [Full Text] [Related]

  • 14. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT, Solomon B.
    Clin Cancer Res; 2011 Apr 15; 17(8):2081-6. PubMed ID: 21288922
    [Abstract] [Full Text] [Related]

  • 15. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.
    Lung Cancer; 2015 Feb 15; 87(2):89-95. PubMed ID: 25576294
    [Abstract] [Full Text] [Related]

  • 16. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.
    Galetta D, Rossi A, Pisconti S, Colucci G.
    Expert Opin Ther Targets; 2012 Apr 15; 16 Suppl 2():S45-54. PubMed ID: 22443113
    [Abstract] [Full Text] [Related]

  • 17. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
    Solomon B, Wilner KD, Shaw AT.
    Clin Pharmacol Ther; 2014 Jan 15; 95(1):15-23. PubMed ID: 24091716
    [Abstract] [Full Text] [Related]

  • 18. Future options for ALK-positive non-small cell lung cancer.
    Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L.
    Lung Cancer; 2015 Mar 15; 87(3):211-9. PubMed ID: 25601484
    [Abstract] [Full Text] [Related]

  • 19. ALK-targeted therapy for lung cancer: ready for prime time.
    Husain H, Rudin CM.
    Oncology (Williston Park); 2011 Jun 15; 25(7):597-601. PubMed ID: 21888258
    [Abstract] [Full Text] [Related]

  • 20. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF.
    Future Oncol; 2014 Oct 15; 10(12):1925-39. PubMed ID: 24856155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.